ACP3 and prostate carcinoma: Sipuleucel-T is a cell-based immunotherapy approach in which a patient’s own antigen presenting cells (APCs) are harvested and activated against prostatic acid phosphatase (PAP), a highly expressed antigen in most prostate cancer cells, then infused back into the patient.